Start-Ups Spun out of SPARK

SPARK has instigated the formation of numerous start-ups working to bring research from bench to bedside


SPARKing Industry in Start-Ups

Alexo Therapeutics

Alexo is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.


Auration Biotech Inc.

Creates products that restore or maintain hearing.


ab initio biotherapeutics

Using a proprietary directed evolution discovery platform to create the next generation of protein therapeutics.


Allertope

Allertope's rapidly-dissolving microneedles form the basis of a new skin test to determine the severity of a person’s food allergies.


Eiger BioPharmaceuticals

  • Researches Hep C/D
  • Company raised over $3.4M from STTR and QTDP grants and $7.1M series A from VCs

Akrotome

  • Tumor imaging
  • $400K in SBIR

Organ-I

Organ-I developed Dx for early kidney rejection; acquired by Immucor. Their product, k-SORT test, is commercially available.


ALDEA Pharmaceuticals (now Aviv Therapeutics)

ALDEA works to combat oxidative stress diseases; a $36M Series A+B. Completing phase 2B trial in Australia.


Balance Therapeutics

Balance researchers Down’s Syndrome; they received $2.2M in SBIR funding, and $21M in series A and B. They are completing a phase 2 clinical trial in Australia.


Altitude Pharma

Altitude is developing a small molecule activator of novel target that both increases insulin sensitivity and endothelial function.


PellePharm

  • Basal cell carcinoma
  • 2014 Harrington Scholar
  • Company raised $8M

Purigen Bio

  • Automated DNA/RNA extraction, quantitation, and enrichment platform
  • Named BayBio FAST Company
  • $150K SBIR

ImmuMetrix

Developed diagnostic for cardiac transplant rejections; acquired by CareDx.


IGIStat

IGIStat developed a diagnostic that can rapidly distinguish between Type 1 (T1D) and Type 2 diabetes (T2D); named BayBio FAST company.


Selten Therapeutics

  • Pulmonary arterial hypertension
  • Granted Orphan Drug Status 3/15.

Sitari Pharmaceuticals

  • Celiac disease
  • $10M series A
  • BriDG collaboration with NCATS to fund IND-enabling studies

Carmenta Bioscience

  • Preeclampsia technology
  • In StartX incubator
  • $80K from March of Dimes
  • Acquired by Progenity

Eiccose Pharmaceuticals

Eiccose raised funding for Phase 2 clinical trial of pulmonary arterial hypertension.


Globavir

  • Anti-viral for Ebola, Dengue and other viruses
  • In StartX incubator
  • Raised Series A & B funding.

Eidos Therapeutics

Eidos developed a novel small molecule to treat transthyretin- based amyloidosis.

SPARK IP licensed or optioned to established companies:

InBios: Cancer

Thiolex Pharma: Cystic fibrosis; commercially available through Bioadvantex Pharma

Jordan River Pharmaceuticals: Brain cancer

La Jolla Pharmaceutical: Neonatal jaundice

InSilixa: Bacterial Diagnostics (*no IP, but co-developing)

Cortice Biosciences: Alzheimer’s disease